Latest Applied genetics Stories
AMSTERDAM, May 10, 2011 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, provided today a status update on Glybera (alipogene tiparvovec), its gene therapy product under development for the treatment of lipoprotein lipase deficiency (LPLD). Following the submission of the Day 180 questions at the end of the first quarter to the European Medicines Agency (EMA) as part of Glybera's Market Authorisation Application...
Overcoming the gene silencing barrier opens doors for gene therapy. Lincoln, NE (PRWEB) April 12, 2011 NTC today announced the award of a Small Business Innovation Research (SBIR) Phase II grant award from the National Institute of General Medical Sciences.
FAIRFIELD, Ohio, April 12, 2011 /PRNewswire/ -- "Hello Truth" has meaning for Robert McClendon, DDC's (DNA Diagnostics Center) first Innocence Network exoneree who was freed through forensic DNA testing in 2008.
FAIRFIELD, Ohio, March 24, 2011 /PRNewswire/ -- DDC (DNA Diagnostics Center), the largest provider of private paternity and other DNA testing in the U.S. and worldwide, announced today that genetics and molecular biology expert Dr.
FORT LEE, N.J., March 16, 2011 /PRNewswire/ -- Neurologix, Inc.
A Wayne State University School of Medicine physician-researcher has developed a personalized therapy to treat a wide range of cancers.
Identigene announced on Tuesday that its DNA Paternity Test Kit is now available in New York pharmacies.
AMSTERDAM, February 8, 2011 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that it will release its financial results for the year ended December 31, 2010 on Wednesday, February 16, 2011 at 07:00 AM Central European Time (CET).
Defects in the genome are the cause of many diseases.
CARLSBAD, Calif., Jan. 10, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that it will hold a conference call focused on Genzyme's recent regulatory discussions with the FDA about the mipomersen NDA filing.
- A political dynamiter.